Cystic Fibrosis (CF) is the most common autosomal recessive genetic disease in Caucasians. It is caused by mutations in the CFTR gene, leading to poor hydration of mucus and impairment of the respiratory, digestive, and reproductive organ functions.
Introduction
Cystic fibrosis (CF) is the most common autosomal recessive genetic disease in Caucasians, where it occurs with a frequency of 1 in 3,000 births, although it is also present at lower rates in populations of non-European descent [1] . CF is caused by mutations in the cystic fibrosis transmembrane conductor regulatory (CFTR) gene, which plays critical functions in epithelial ion transport and hydration of mucus. Absent or reduced CFTR activity results in thick, viscous secretions that impair functions of the respiratory, digestive, and reproductive organ systems.
Multiple advances in medical care in CF, once a fatal pediatric disease, have led to remarkable gains in patient life expectancy. However, increased longevity of CF patients into adulthood has led to new challenges, such as gastrointestinal cancer. The average onset of colorectal cancer (CRC) in CF patients is approximately 20-30 years earlier than in the general population [2, 3] . Systematic data on colonoscopic screening and surveillance suggest that CF-associated CRC arises via the classical adenoma to cancer sequence, but adenomatous polyps develop at a younger age in CF and broad-spectrum antibiotics.
Here, we compare the mucosal microbiome (via 16S rRNA sequencing) and colonic gene expression (via RNA-seq) in adult patients with CF and healthy controls undergoing CRC screening by colonoscopy. We explore interactions between the gut microbiome and host gene regulation by integrative analysis, characterizing genes and microbes that may play a joint role in the development of CRC in CF patients.
Methods

Patients and mucosal biopsy samples
Mucosal biopsies were obtained from patients undergoing CRC screening and surveillance colonoscopies at the University of Minnesota. The majority of CF patients receiving care at the Minnesota Cystic Fibrosis Center participate in a systematic colonoscopic CRC screening program as described previously [4] . Control samples were obtained from non-CF patients undergoing routine colonoscopic CRC screening or surveillance. Pinch biopsies, four per patient, were obtained using the Radial Jaw 4
Jumbo w/Needle 240 (length) forceps for 3.2 mm working channel (Boston Scientific, Marlborough, MA; Catalog # M00513371) in the right colon and placed into RNAlater stabilization solution (ThermoFisher Scientific, Waltham, MA). The protocol was approved by the University of Minnesota Institutional Review Board (IRB protocol 1408M52889). Gene expression was analyzed by RNA-Seq from a total of 33 samples obtained from 18 CF patients and 15 non-CF control participants (Fig S1) .
RNA extraction and sequencing
Biopsy tissue was kept in the RNAlater stabilization solution overnight at 4 o C. RNA was prepared following tissue homogenization and lysis using the TRIzol Plus RNA Purification Kit (ThermoFisher Scientific; catalogue # 2183-555) following detailed manufacturer instructions. Total RNA samples were converted to Illumina sequencing libraries using Illumina's Truseq Stranded mRNA Sample Preparation Kit (Cat. # RS-122-2103). Total RNA is oligo-dT purified using oligo-dT coated magnetic beads, fragmented and then reverse transcribed into cDNA. The cDNA is adenylated and then ligated to dual-indexed (barcoded) adaptors and amplified using 15 cycles of PCR. Final library size distribution is validated using capillary electrophoresis and quantified using fluorimetry (PicoGreen). Indexed libraries are then normalized, pooled and then size selected to 320bp +/-5% using Caliper's XT instrument. Truseq libraries are hybridized to a paired end flow cell and individual fragments are clonally amplified by bridge amplification on the Illumina cBot. Once clustering is complete, the flow cell is loaded on the HiSeq 2500 and sequenced using Illumina's SBS chemistry (Fig S1) .
Host RNA-seq quality control, read mapping and filtering
We performed quality check on raw sequences from all 33 samples to assure better downstream analysis using FastQC [24] . This helped assess any biases due to parameters such as quality of the reads, GC content, number of reads, read length and species to which the majority of the reads mapped (Fig S2) . The FASTQ files for forward and reverse (R1 and R2) reads were mapped to the reference genome using kallisto [25] , where an index for the transcriptomes was generated to quantify estimated read counts and TPM values. Mean distribution for the TPM values was plotted using R to filter all the transcripts below a threshold value of log2[TPM] < 0. We generated PCA plots using sleuth [26] to examine sample clusters and visualization of expression patterns for genes using bar plots (Fig S3 and Fig S4) . For further analysis of outlier samples box plots were generated using Cook's distance and heat map clustered by condition and mutation status was generated for the top 20 expressed genes ( Fig S5 and Fig S6) .
Host RNA-seq differential expression and enrichment analysis
To determine differentially expressed genes between CF and healthy samples we quantified and annotated the transcripts used DESeq2 [27] . The output from kallisto was imported into DESeq2 using the tximport package [28] . The transcripts were annotated against the ensemble database using bioMART to obtain gene symbols [29] .
Transcripts below a threshold of row-sum of 1 were filtered and collapsed at gene symbol level. Prior to differentially expressed gene analysis, the read counts were normalized and the gene-wise estimates were shrunken towards the fitted estimates represented by the red line in the dispersion plot (Fig S7) . The gene-wise estimates that are outliers are not shrunk and are flagged by the blue circles in the plot (Fig S7) .
DESeq2 applies the Wald test on estimated counts and uses a negative binomial generalized linear model determines differentially expressed genes and the log-fold changes (Fig S8) . The log-fold change shrinkage (lcfshrink()) function was applied for ranking the genes and data visualization. For data smoothing, MA plots were generated before and after log2 fold shrinkage. We found no change in the MA plot ( Fig S9) post smoothing, as there are no large log-fold changes in the current data (log2 fold change between -1 and 1) due to low counts. The data were further transformed and the normalized values were extracted using regularized logarithm (rlog) to remove the dependence of variance on mean. We used the Benjamini-Hochberg method for reducing the false discovery rate (FDR) with a cutoff of 0.05 for identifying differentially expressed genes for further analysis. Enrichment analysis was done using Ingenuity Pathway Analysis (IPA, QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis). The logfold changes, p-values, and FDR values (for all the genes with FDR < 0.05) were fed into IPA for both up-and down-regulated differentially expressed genes between CF and healthy samples. Disease/functional pathways and gene networks were determined based on the gene enrichment. Furthermore, we looked at how many target upstream regulators were enriched based on our list of differentially expressed genes using IPA.
We found 134 targets that passed the filter (p-value < 0.01) from a total of 492 targets, of which 96 were transcription regulators. Gut mucosal microbiome data processing, quality assessment, and diversity analysis We processed the FASTQ files using FastQC [24] to perform quality control on the raw sequences. We then used SHI7 [31] for trimming Nextera adaptors, stitching paired-end reads and performing quality trimming at both ends of the stitched reads until a minimum Phred score of 32 was reached. Following quality control, we obtained an average of 217,500 high quality reads per sample (median 244,000; range 9551 -373,900) with an average length of 281.9 bases and an average quality score of 37.19.
16S rRNA extraction and sequencing
These merged and filtered reads were used for closed reference OTU picking and taxonomy assignment against GreenGenes database with 97% similarity level using the NINJA-OPS program [32] .
We performed alpha and beta-diversity analysis in R using the vegan [33] and phyloseq [34] packages. We used resampling-based computation of alpha-diversity, where the OTU table is subsampled 100 times at minimum read depth (9551 reads) across all samples, and computed average richness estimate for each alpha-diversity metric (chao1, observed-OTUs, and Shannon). Wilcoxon rank-sum test was used for testing the statistical significance of the associations between alpha-diversity of the CF and healthy conditions. For computing beta-diversity, we first rarefied the OTU table (using vegan's rrarefy() function) at minimum sequence depth (i.e. 9551 reads) across the samples and then computed Bray-Curtis dissimilarity, weighted UniFrac, and unweighted UniFrac metrics. The Adonis test was used for assessing if there is significant association between the beta-diversity of the CF/healthy condition and the diversity results are plotted using the ggplot2 package in R.
Gut mucosal microbiome differential abundance and functional analysis
We performed differential abundance testing using the phyloseq [34] package in R. We first created a phyloseq object from the OTU table (using the phyloseq() function) and filtered this object to only include OTUs with at least 0.1% relative abundance occurring in at least half of all samples (using the filter_taxa() function). The filtered phyloseq object was converted into a DESeqDataSet object (using phyloseq_to_deseq2()) and the DESeq() function was invoked. This performed dispersion estimations and Wald's test for identifying differentially abundant OTUs, with their corresponding log-fold change, p-value, and FDR-adjusted q-values between the CF and healthy conditions. We agglomerated the OTUs at different taxonomic ranks (using the tax_glom() function) and repeated the above steps to identify differentially abundant taxa at genus, family, order, class, and phylum levels.
We also tested for associations between taxonomic abundance and mutation status of CF samples. We first categorized samples into three genotype categories: (1) Healthy:
Samples with no mutations; (2) CF_df508: CF samples with homozygous delta-F508 deletion, which is associated with more severe CF condition [35] ; and (3) CF_other: CF samples with df508 heterozygous deletion or other mutation status. We used DESeq2's likelihood ratio test (LRT) to identify taxa that showed significant difference in abundance across the three categories.
We then generated the predicted functional profiles for the gut microbes using PICRUSt v1.0.0 pipeline, [36] where pathways and enzymes are assigned using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. The KEGG level 3 pathways were filtered for rare pathways by only including pathways with relative abundance > 0.1% in at least half of the samples, normalized to relative abundance, and tested for association with CF/Healthy conditions using non-parametric Wilcoxon rank-sum test followed by FDR adjustment. taxa) statistical tests were performed, and p-values were corrected for multiple comparisons using the qvalue package in R [37] . Representative gene-taxa correlations were visualized using corrplots [38] in R, where the strength of the correlation is indicated by the color and size of the visualization element (square) and the significance of the correlation is indicated via asterisk. We also computed the Sparse Correlation for Compositional Data (SparCC) [39] for the taxa found significantly correlated (q-value < 0.1) with the CRC genes. Pseudo p-values were computed using 100 randomized sets.
Integrated analysis of interactions between host gene dysregulations and changes in microbiome
Significant gene-microbe correlations (q-value < 0.1) and significant microbe-microbe correlations (SparCC |R| >=0.1 and p-value <0.05) were visualized as a network using Cytoscape v3.5.1 [40] .
Results
Host RNA-Seq sample preprocessing and quality assessment
We first examined gene expression in colonic biopsies from 18 CF and 15 healthy individuals. Overall, CF and healthy samples had comparable number of reads (28, 250 ,473 and 30,041,827 reads on average, respectively) with the average quality greater than 30 phred score across all samples (Fig S2) . The sequences were annotated to generate estimated read counts and transcripts per kilobase million (TPM) using kallisto, [25] resulting in 173,259 total transcripts, of which 56,283 passed the filter of mean TPM greater than 1 (TPM>1). While the Principal component analysis (PCA) plots showed an overlap between the expression profile of most samples from CF and healthy individuals, it identified two possible outliers (samples 1096 and 1117) (Fig S3) .
In addition, the top five transcripts driving the PC were of mitochondrial origin (Fig S4) .
Hence, to reduce any bias in identifying differentially expressed genes, we filtered out all the mitochondrial transcripts from the data. We further investigated the outliers using the remaining transcripts by calculating cook's distance between the samples, and found that the two samples (1096 and 1117) were still outliers (Fig S5) . This was further evident by the heatmap of the top 20 most highly expressed genes (Fig S6) , where we found an alternate expression pattern for the two samples, compared to the rest. Therefore, the two outlier CF samples (1096 and 1117) were eliminated from further analysis.
Differentially expressed host genes between CF and healthy mucosal samples
To examine gene expression differences we used read counts from the remaining 16 CF and 15 healthy samples. Using DESeq2 we identified 1543 differentially expressed genes at q-value < 0.05 (Benjamini-Hochberg correction; see Fig S8 for a volcano plot) .
Of the 1543 differentially expressed genes, 919 (59%) were up-regulated and 624 (41%) were down-regulated in CF patients. Including sex as a covariate in the model did not susbstantially alter the results (only 43 additional differentially expressed genes were identified); therefore, we did not include sex in downstrem analyses. The full list of differentially expressed genes significant at q-value < 0.05 is available in Additional File 2.
We visualized the expression pattern of six representative genes, selected from genes included in the colorectal cancer disease pathway ( Figure 1A) . Consistent with the expectation of changes in mucosal immunity that could compensate for a diminished protective mucus function, we noted LCN2 to be one of the top differentially expressed genes (q-value = 2.54E-08, Wald test). LCN2 encodes for lipocalin 2, which limits bacterial growth by sequestering iron-laden bacterial siderophore [41] . However, a number of other top genes are involved in major cellular biology processes, and were previously related to cancer pathogenesis and colon cancer. Examples include RRS1 (q-value = 6.16E-09), which encodes for the ribosomal biogenesis protein homolog that promotes angiogenesis and cellular proliferation, but suppresses apoptosis [42] ; KRTAP5-5 (q-value = 4.89E-08), which encodes for keratin-associated protein 5-5, a protein that plays important roles in cytoskeletal function and facilitates various malignant behaviors that include cellular motility and vascular invasion [43] ; ALDOB (qvalue = 2.64E-07), which encodes for aldolase B, an enzyme that promotes metastatic cancer-associated metabolic reprogramming [44] . Additional examples of differentially expressed genes (Log-fold change > 0.5 and q-value < 0.05), such as CDH3, TP53INP2, E2F1, CCND2, and SERPINE1, were also previously shown to have direct roles in colorectal and digestive cancers [45] [46] [47] . While, some of these genes participate in basic cancer-related cellular functions such as proliferation and invasion [45] [46] [47] [48] [49] [50] [51] [52] , others, e.g. BEST2, play important roles in gut barrier function and anion transport [53, 54] . In addition to the genes visualized in Figure 1A , additional randomly selected differentially expressed genes are visualized in Additional File 1 (Fig S10) , showing expression pattern difference between the CF and healthy samples. and colorectal cancer, respectively [55, 56] . NHF4A is involved in transcriptional regulation of many aspects of epithelial cell morphogenesis and function, which has been linked to colorectal cancer [57] . CST5, which encodes cytostatin D, is a direct target of p53 and vitamin D receptor, promotes mesenchymal-epithelial transition to suppress tumor progression and metastasis [58] . E2F3 is a potent regulator of the cell cycle and apoptosis that is commonly deregulated in oncogenesis [59, 60] .
A metabolic network for the gastrointestinal (GI) cancer-related differentially expressed genes is shown in Figure 1C , illustrating the interactions between genes that are upregulated in CF (Eg. TP53INP1, SERPINE1, NCOR1 and CAPN2) and down-regulated in CF (E2F1, MED1, ECND2 and AS3MT), highlighting the cellular location of these genes' product. Additional gene network for colorectal cancer can be found in Additional file 1 (Fig S12) , where the genes are also positioned in the region of the cell where they are most active. We found that genes such as BEST2 (involved in ion transport) and RUVBL1 (involved in cell cycle, cell division, and cell damage) are down-regulated, while genes such as TP53INP2 (involved in transcription regulation) and CDH3 (involved in sensory transduction) are up-regulated. Given the predicted role of gene regulation in colorectal cancer and the dysregulation of CRC-related pathways, these results may help understand mechanisms controlling early onset of colon cancer in cystic fibrosis.
Difference in microbiome composition between CF and healthy gut mucosa
To further understand the potential of altered microbiota-host interaction in the CF colon, we next investigated differences in the composition of the mucosal microbiome between CF and healthy individuals. We found a significant difference between betadiversity of gut mucosal microbiome in CF patients compared to healthy individuals with respect to unweighted UniFrac and non-phylogenetic Bray-Curtis metrics (Adonis pvalue = 0.001). As observed in the PCoA plot (Figure 2A ) the samples were clustered based on their disease condition (CF or healthy). The overall biodiversity of mucosal microbiome was depleted in CF compared to healthy samples, which is depicted by significant decrease in alpha diversity measured by Chao1 (p-value = 0.015, Wilcoxon rank sum test, Figure 2A ) and Observed OTUs (p-value = 0.024, Wilcoxon rank sum test, in Additional File 1 (Fig S13) ) metrics in CF relative to healthy controls.
We assessed the changes in abundance of microbes at various taxonomic levels between CF and healthy gut mucosal microbiome using phyloseq. We found 51 OTUs that were significantly differentially abundant between CF and healthy individuals (qvalue < 0.1, Additional file 3). At different taxonomic ranks, we found 7 genera, 10 families, 4 orders, 4 classes, and 5 phyla differentially abundant between CF and healthy samples (q-value < 0.1 by Wald's test; Additional file 3). Overall, an increased abundance in taxa, predominantly belonging to Firmicutes and Fusobacteria, was observed in CF individuals compared to healthy controls, while taxa belonging to Bacteroidetes, Verrucomicrobia, and Proteobacteria phyla showed a marked decrease in patients with CF relative to healthy controls ( Figure 2B ). In particular, there was an increase in abundance of class Actinobacteria in individuals with CF compared to healthy controls (q-value = 0.079), while Butyricimonas (q-value = 0.009), Ruminococcaceae (q-value = 0.081), Sutterella (q-value=0.040) were found depleted in CF samples (Figure 2C) . Additional examples of differentially abundant taxa between CF and healthy samples can be found in the Additional file 1 (Fig S14) .
Next, we tested whether CFTR genotype, which affects disease severity, is associated with variation in the microbiome. Specifically, we hypothesized that variation in the microbiome is correlated with the number of alleles of the DF508 mutation, a deletion of an entire codon within CFTR that is the most common cause for CF. To test this, we performed likelihood ratio test to identify differentially abundant taxa between three genotype classes: CF-DF508 (homozygous for the DF508 mutation), CF-other (either one or zero copies of the DF508 mutation), and healthy (no known mutations in CFTR).
We found a gradient-like trend in abundance for Actinobacteria (q-value = 0.081), showing increase in abundance with increasing severity of mutation status ( Figure 2D) .
To assess the potential functional changes in the microbiome, we predicted abundance of metabolic pathways and enzymes using the PICRUSt pipeline [36] and KEGG database, and compared them for differences between CF and healthy individuals.
Seven predicted pathways (as defined by KEGG level 3) were found to be differentially abundant between CF and healthy: bacterial toxins were enriched in CF compared to healthy, while propanoate metabolism, restriction enzyme, pantothenate and CoA biosynthesis, thiamine metabolism, amino acid related enzymes, and aminoacyl-tRNA biosynthesis were depleted in CF compared to healthy (q-value < 0.2 using Wilcoxon rank sum test; in Additional File 1 (Fig S15) ).
Interactions between gastrointestinal cancer-related host genes and gut microbes
In order to investigate the relationship between host genes and microbes in the colonic mucosa and their potential role in the pathogenesis of gastrointestinal cancers in CF patients, we considered correlations between 250 differentially expressed genes enriched for GI cancers and 35 microbial taxa (collapsed at genus or last characterized level, and filtered at 0.1% relative abundance, see Methods). Using Spearman correlations, we found 50 significant unique gene-microbe correlations in the gut (qvalue < 0.1), where the magnitude of correlation (Spearman rho) ranged between (-0.77, 0.79) (Additional file 4). Interestingly, most of the taxa that significantly correlated with the genes also differed significantly in abundance between CF and healthy individuals. We visualized all the correlations between taxa abundance and host gene expression in Figure 3A . In particular, we found some significant positive gene-taxa In addition to the overall network, Figure 3C depicts pairwise correlations between host gene expression and microbial taxa where both have been previously linked to CRC, and thus may be of interest. For example, LCN2, known to be overexpressed in human CRC and other cancers (Maier et al. 2014) , is negatively correlated with Ruminococcaceae (Spearman rho = -0.77, q-value = 0.040), which is found depleted in CRC [61, 62] . Both DUOX2 and DUOXA2 are found to be negatively correlated with Christensenellaceae (Spearman rho < -0.65, q-value < 0.1), while DUOXA2 is positively correlated with Veillonella (Spearman rho = 0.70, q-value = 0.082). DUOX2 and its maturation factor DUOXA2 are responsible for H2O2 production in human colon and are known to be up-regulated in gastrointestinal inflammation [63, 64] .
Christensenellaceae, a heritable taxon [65] , has been shown to decrease in abundance in conventional adenoma [62] , a precursor of CRC, whereas Veillonella, which is known to be pro-inflammatory, is found to be represented in human CRC [66] . Thus, the pattern of grouping by CF and healthy samples in these representative correlations are found to be similar to known associations in CRC and other gastrointestinal malignancies.
Discussion
Recent advances in the treatment have significantly prolonged the lives of CF patients [67, 68] . However, this led to new challenges, such as an elevated risk for gastrointestinal cancer [2, 69] . Thus, CF patients show 5-10-fold increased risk of CRC compared to healthy individuals, and that increases even further with immunosuppressive drugs [3, 6] . Understanding the molecular mechanisms that control the increased risk is key for early detection and the development of tailored treatments [6] . The importance of interactions between host and microbiome in the pathogenesis of colorectal cancer has become increasingly clear [61, 70, 71] . To understand the role of these interactions in CF, we jointly profiled host colon gene expression and mucosal microbiome composition data in CF patients and healthy controls. We observed an enrichment of cancer-associated dysregulated genesspecifically colon cancer -in CF patients compared to healthy controls. We also observed a shift in the microbiome and identified strains previously linked to colon cancer that varied in their abundance between CF and healthy individuals. We further found relevant correlations between these cancer enriched genes and microbes that may illuminate the mechanisms of CRC development in CF patients.
Several previous studies have studied the role of host gene regulation in CF patients [5, 72, 73] . While results from previous studies are based on either phenotypic observations, examining candidate genes such as CFTR, or an exploration of gene expression data from respiratory or blood samples [5, 72, 73] , our work is the first, as far as we know, that focused on a comprehensive transcriptomic analysis of colon biopsies.
This allowed us to characterize patterns of host gene regulation specific to the CF colon epithelium. In addition to an enrichment of cancer-related pathways among genes that are differentially expressed in CF, we also observed an enrichment for immune response pathways, including signal transduction, cell adhesion, and viral infection.
Interestingly, one of the most significant pathways enriched in our current data, the eIF2 signaling pathway, has been previously shown to play an important role in immune response, and cells with defective eIF2 signaling pathway were more susceptible to bacterial infections [74] . In addition, our analysis revealed that tumor suppressor genes are differentially regulated in the colon of CF patients. In addition to CFTR, we found other tumor suppressor genes, such as HPGD, to be down-regulated in CF patients colon. HPGD was previously shown to be down-regulated in lungs of CF patients [5, 75] . Down-regulation of these tumor suppressor genes can lead to predisposition of colon cancer [42, 76, 77] , suggesting a potential mechanism underlying the reported increased risk and early development of colon cancer in CF patients [5, 69] .
In addition to host gene regulation, the microbiome has also been implicated in the development of many diseases, including CRC [61, 78] . In the context of CF, previous studies have focused on characterizing shifts in the fecal or airway microbiome [20, 79] .
Here, we profiled the colonic mucosal microbiome, with the goal of understanding its role in the development of CRC in CF patients. We found a clear distinction between microbiome populations from CF compared to healthy mucosa. Overall, similar to several other GI diseases, we also observed a reduced microbial biodiversity in the CF population [80] . We also found a depletion in butyrate producing bacteria, such as Ruminococcaceae and Butyricimonas, similar to previously reported depletion in butyrate producing microbes by Manor et al [20] in their study comparing CF fecal samples from children on varying degree of fat intake. Butyrate helps promote growth and can also act as an anti-inflammatory agent, and is therefore an important compound for colon health [20] . Interestingly, mice with compromised GI defense system also had a reduced number of butyrate producing bacteria, similar to our observations in the CF patients, who generally consume a high fat diet [81] . In addition to decrease in Ruminococcaceae, we also observed a depletion in another butyrate producing bacteria Sutterella; loss of abundance in both of these strains have been previously observed in CRC [61, 82] . We also found an increase in Actinobacteria, one of the most predominant genera found in the sputum of CF patients [79, 83] , but decreased in colon cancer gut microbiome [84] . Furthermore, our observation of significant decrease in the abundance of Verrucomicrobia, and increase in abundance of Firmicutes and Actinobacteria in CF patients, is consistent with findings from the fecal microbiome of CF patients [21] . Lastly, we found an increase in predicted bacterial toxins in the CF population, which might be explained by the increase in pathogenic bacteria such as Pseudomonas and Veillonella. This can potentially damage epithelial cells or induce mutations leading to unfavorable clinical outcome [85, 86] .
Integrating mucosal microbiome and host gene expression profiles, we observed several correlations between differentially expressed colon epithelial genes and gut mucosal bacteria in CF. Co-culture and obligate cross-feeding studies have shown an increased virulence of a pathogen in the presence of other bacteria, thus triggering an immune response that can determine the clinical outcome [87, 88] . One such example is the increased virulence of Pseudomonas in presence of Veillonella as seen in mice tumor model resulting in host clinical deterioration [88] . Interestingly, we found both of these microbes (Veillonella and Pseudomonas) in higher abundance in CF patients.
Furthermore, we also found a strong correlation between Veillonella and DUOXA2, a highly expressed gene causing inflammation in ulcerative colitis [89] . Another such correlation that we observed was between highly expressed LNC2 gene, which plays a role in innate immunity and has been previously found to be up-regulated in human colon cancers [90] , and depletion of Ruminococcaceae, a butyrate producing bacteria that helps maintain colon health [20] .
Our study has several limitations. First, CF patients have a high burden of antibiotic exposure. Since antibiotics affects the gut microbiome [91] [92] [93] , this may impact the differences we observe between CF and healthy mucosal microbiome. It is challenging to account for this potential bias; although matched healthy controls that are also on antibiotics can be used, the effects of long-term antibiotics usage may be impossible to match in a non-CF control population. In addition, although we report potential host gene-microbe and microbe-microbe interactions, our study focused on correlations, and causality is not inferred. Although studying causality in host-microbe is challenging in humans, future studies using animal or cell models can be useful to disentangle the direction of interaction [94] .
Conclusions
To summarize, we report an analysis of the mucosal microbiome and host gene expression in the gut of CF patients and healthy controls. We find down-regulation of tumor suppressor genes, as well as up-regulation of genes that play a role in immune response and cause inflammation. Furthermore, we observe a shift in microbiome with depletion in butyrate producing bacteria that may help maintain colon health and increase in pathogenic strains in individuals with CF. Lastly, our study provides a set of candidate interactions between gut microbes and host genes in the CF gut. ABCA9  ALYREF  ATIC  CCDC28A  CDC6  CDC7  CDCA7  CMIP  DPP10  DUOX2  DUOXA2  EIF3J  FAM111B  FAM120C  GCNT4  GINS1  GINS2  GSTO1  HELLS  ILDR1  KIRREL3  LCN2  LRPPRC  MCM4  MDN1  MRPL17  MUC5AC  NAPSA  NUDCD1  NUDT14  PAICS  PPP1R14B  PTGFR  RPLP2  SESN3  TAT  TBX10  TFAM  TICAM1  TMEM97  TRHDE  UCP3  UNG  ZC3H12A 
